Intellia Therapeutics (NTLA) PT Raised to $110 at Roth Capital After First In-Person Data with a Clean Safety Profile

Roth Capital analyst Tony Butler raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $110.00 after a presentation by Dr. Julian Gilmore of University College London at the 2021 Peripheral Nerve Society meeting highlighted the first-in-human data from the NTLA-2001 program demonstrated a mean TTR reduction of up to 87% at the higher dose level with a clean safety profile.

The analyst reiterated a Buy rating, stating "Patients experienced a dose-dependent reduction in circulating serum TTR levels upon receiving NTLA-2001. One patient at the 0.3 mg/kg dose level experienced a 96% reduction in TTR level at day 28. The mean reduction was 87%,. Intellia intends to achieve a 90% or greater mean reduction in TTR. Therefore, dose escalation will continue at the next level of 1.0 mg/kg."

You May Also Be Interested In

• Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
• Brinker Int'l (EAT) PT Raised to $260 at DA Davidson, Neutral Rating Maintained
• Kontoor Brands (KTB) PT Raised to $136 at UBS on Long-Term Opportunities